Page 48 - Read Online

Terai et al. The liver and metastatic uveal melanoma

DS,Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP. Memorial Sloan-Kettering Cancer Center, and University Hospital of
Parallel profiling of immune infiltrate subsets in uveal melanoma Lausanne experience. Cancer 2013;119:3687-95.
versus cutaneous melanoma unveils similarities and differences: a pilot 63. Javed A, Arguello D, Johnston C, Gatalica Z, Orloff MM, Mastrangelo
study. Oncoimmunology 2017;6:e1321187. MJ, Sato T. Disparity in PD-L1 expression between metastatic uveal and
55. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves cutaneous melanoma. J Clin Oncol 2016;ASCO 2016:abstract 9541.
CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato 64. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens
T. High-dose immunoembolization: survival benefit in patients with MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N,
hepatic metastases from uveal melanoma. Radiology 2009;252:290-8. Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan
56. Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg
I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, PD, Taylor EJ,Munster PN, Algazi AP, Chmielowski B, Dummer R,
Berd D, Mastrangelo MJ, Sato T. Double-blinded, randomized phase Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce
II study using embolization with or without granulocyte-macrophage RH, Daud A. Liver metastasis and treatment outcome with anti-PD-1
colony-stimulating factor in uveal melanoma with hepatic metastases. monoclonal antibody in patients with melanoma and NSCLC. Cancer
Immunol Res 2017;5:417-24.
J Vasc Interv Radiol 2015;26:523-32.e2. 65. Chandran SS, Somerville RP, Yang JC, Sherry RM, Klebanoff CA,
57. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan
JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey
van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, MA, Rosenberg SA, Kammula US. Treatment of metastatic uveal
Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, melanoma with adoptive transfer of tumour-infiltrating lymphocytes:
Wolchok JD,Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol
WJ. Improved survival with ipilimumab in patients with metastatic 2017;18:792-802.
melanoma. N Engl J Med 2010;363:711-23. 66. Rothermel LD, Sabesan AC, Stephens DJ, Chandran SS, Paria BC,
58. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Srivastava AK, Somerville R, Wunderlich JR, Lee CC, Xi L, Pham
Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio TH, Raffeld M, Jailwala P, Kasoji M, Kammula US. Identification of
M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya an immunogenic subset of metastatic uveal melanoma. Clin Cancer
K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok Res 2016;22:2237-49.
JD. Ipilimumab plus dacarbazine for previously untreated metastatic 67. de Vries TJ, Trancikova D, Ruiter DJ, van Muijen GN. High expression
melanoma. N Engl J Med 2011;364:2517-26. of immunotherapy candidate proteins gp100, MART-1, tyrosinase and
59. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, TRP-1 in uveal melanoma. Br J Cancer 1998;78:1156-61.
Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, 68. Bol KF, Mensink HW, Aarntzen EH, Schreibelt G, Keunen JE, Coulie
Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton PG, de Klein A, Punt CJ, Paridaens D, Figdor CG, de Vries IJ.Long
JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, overall survival after dendritic cell vaccination in metastatic uveal
durable tumor remission, and long-term safety in patients with advanced melanoma patients. Am J Ophthalmol 2014;158:939-47.
melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30. 69. Middleton MR, Corrie P, Sznol M, Infante J, Mulatero C, Evans J,
60. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats Steven N, Krige D, Shingler WH, McGrath Y, Hassan NJ, Jakobsen
JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal BK. A phase I/IIa study of IMCgp100: partial and complete durable
RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical responses with a novel first-in-class immunotherapy for advanced
outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 melanoma. Cancer Res 2015;75:abstract CT106.
antibodies. Cancer 2016;122:3344-53. 70. Sato T, Nathan PD, Hernandez-Aya LF, Sacco JJ, Orloff MM, Truscello
J, McAlpine C, Hulstine A-M, Lanasa MC, Coughlin CM, Carvajal
61. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi RD. Intra-patient escalation dosing strategy with IMCgp100 results in
R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, mitigation of T-cell based toxicity and preliminary efficacy in advanced
Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto uveal melanoma. J Clin Oncol 2017;ASCO 2017:abstract 9531.
PA. Efficacy and safety of ipilimumab in patients with pre-treated, 71. Esmaeli B, Williams MD, Soheili A, Gombos DS, Simantov R.
uveal melanoma. Ann Oncol 2013;24:2911-5. GPNMB expression in uveal melanomas: a potential for targeted
62. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth therapy. Invest Ophthalmol Vis Sci 2009;50:3385.
M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty 72. Patel S, Lewis KD, Olencki T, Hernandez-Aya L, Joseph R,
KT, Sullivan RJ, Harding JJ, D’Angelo S, Dickson M, Schwartz GK, Williamson S, Chandra S, Shirai K, Moscow J. A Phase II Study of
Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity Glembatumumab Vedotin for Metastatic Uveal Melanoma. Avaliable
of ipilimumab for metastatic uveal melanoma: a retrospective review from: http://www.melanomacongress.com/docs/2017_abstracts.pdf.
of the Dana-Farber Cancer Institute, Massachusetts General Hospital, [Last accessed on 23 Oct 2017]

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ October 31, 2017 243